PARG Inhibitor PDD00017273

Cat. No. GTX02570

	1 mg
PRODUCT	
Summary	Human poly(ADP-ribose) glycohydrolase (PARG) inhibitor for in vitro studies. Inhibits human recombinant PARG enzymes ($IC_{50}=26nM$) and PARG in cell assays ($IC_{50}=37nM$). Inactive against related glycohydrolases ARH3 and PARP1s ($IC_{50}>30\mu M$). Showed no cytotoxicity ($IC_{50}>30\mu M$). Poly(ADP ribose) glycohydrolase (PARG) is a critical component in the repair of single strand DNA breaks and therefore a target in cancer cells. PARG counteracts the function of the ARTD family of poly(ADP ribose) polymerases (known as PARPs) by efficiently catalysing the hydrolysis of O-glycosidic linkages of ADP-ribose polymer, thereby reversing the effects of PARPs. CAS No. : 1945950-21-9 Appearance : White to off-white solid Formula : $C_{23}H_{26}N_6O_4S_2$ Molecular weight : 514.6
Properties	
Form	Lyophilized powder
Buffer	Soluble in DMSO (10mg/ml), methanol or acetonitrile (1mg/ml)
Preservative	No preservative
Storage	Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.
Purity	> 98% (HPLC); ⁱ H-NMR (Conforms)
Conjugation	Unconjugated
Note	For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption. Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.

Package



For full product information, images and publications, please visit our <u>website</u>.

Date 2025 / 06 / 02 Page 1 of 1